UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549



	FORM 8-K CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 10, 2014

CATALENT PHARMA SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)



Delaware (State or other jurisdiction of Incorporation)	333-147871 (Commission File Number)		13-3523163 (IRS Employer Identification Number)

14 Schoolhouse Road Somerset, New Jersey		08873
(Address of registrant’s principal executive office)		(Zip code)

(732) 537-6200
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On February 10, 2014, Catalent Pharma Solutions, Inc. (the “Company”) issued an earnings release setting forth the Company’s second quarter ended December 31, 2013 financial results. The earnings release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

As provided in General Instruction B.2 of Form 8-K, the information and exhibit contained in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act’), nor shall they be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.


(d)	Exhibits. The following Exhibit is furnished as part of this Current Report on Form 8-K.

Exhibit No. Description


99.1	Earnings release, February 10, 2014, issued by Catalent Pharma Solutions, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Catalent Pharma Solutions, Inc.

(Registrant)

By: _/s/ Samrat S. Khichi ______

Name: Samrat S. Khichi

Title: Senior Vice President, Chief Administrative Officer, General Counsel and Secretary

Date: February 10, 2014

EXHIBIT LIST

Exhibit No. Description


99.1	Earnings release, February 10, 2014, issued by Catalent Pharma Solutions, Inc.

Catalent Pharma Solutions, Inc. 8-K